National Institute of Cardiology Becomes First Hospital in Poland to Establish Advanced Robotic Program to Treat Heart Rhythm Disorders
March 24 2022 - 9:06AM
Stereotaxis (NYSE: STXS), the global leader in innovative robotic
technologies for the treatment of cardiac arrhythmias, announces
that Poland’s National Institute of Cardiology, the leading
clinical center of cardiology and cardiac surgery in Warsaw, has
established the first robotic electrophysiology program in the
country with Stereotaxis’ Genesis Robotic Magnetic Navigation (RMN)
system. The National Institute of Cardiology is the only hospital
in Poland offering advanced robotic technology to improve the
minimally invasive treatment of heart arrhythmias.
A 2019 study reported that 3.8% of Warsaw
residents aged 20-65 had an arrhythmia with the prevalence of
arrhythmia increasing to 18.6% for those over age 65. By this
estimate, over 2 million individuals in Poland may suffer from
arrhythmias.
“We are proud to pioneer advanced medical
technology in Poland and to be one of the first three hospitals in
Europe using the advanced Genesis RMN technology to improve the
care of patients who suffer from arrhythmias,” said Prof. dr. hab.
n. med. Lukasz Szumowski, director of the National Institute of
Cardiology.
The Genesis RMN system introduces the benefits
of robotic precision and safety to cardiac ablation, a common,
minimally invasive procedure to treat arrhythmias. Tens of millions
of individuals worldwide suffer from arrhythmias – abnormal heart
rhythms that result when the heart beats too quickly, too slowly,
or with an irregular pattern. When left untreated, certain
arrhythmias can significantly increase the risk of stroke, heart
failure, and sudden cardiac arrest.
“We are proud that we can bring this new and
innovative robotic technology to Poland,” says Leszek Piątek, Vice
President of Consultronix, distributor of advanced medical
equipment in Poland. “We are confident it will have a significant
impact on improving cardiology patient care in Poland and will
provide a new quality of electrophysiology treatments. Providing
the best medical solutions is and always will be the goal of
Consultronix.”
“We are delighted to partner with the National
Institute of Cardiology and Consultronix to pioneer the benefits of
Robotic Magnetic Navigation in Poland,” said David Fischel,
Chairman and CEO of Stereotaxis. “We look forward to supporting
their efforts to improve patient care and advance clinical
science.”
About StereotaxisStereotaxis is
the global leader in innovative robotic technologies designed to
enhance the treatment of arrhythmias and perform endovascular
procedures. Its mission is the discovery, development and delivery
of robotic systems, instruments, and information solutions for the
interventional laboratory. These innovations help physicians
provide unsurpassed patient care with robotic precision and safety,
expand access to minimally invasive therapy, and enhance the
productivity, connectivity, and intelligence in the operating room.
Stereotaxis technology has been used to treat over 100,000 patients
across the United States, Europe, Asia, and elsewhere. For more
information, please visit www.stereotaxis.com.
This press release includes statements that may
constitute "forward-looking" statements, usually containing the
words "believe”, "estimate”, "project”, "expect" or similar
expressions. Forward-looking statements inherently involve risks
and uncertainties that could cause actual results to differ
materially. Factors that would cause or contribute to such
differences include, but are not limited to, the Company's ability
to manage expenses at sustainable levels, acceptance of the
Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to
purchase its technology, competitive factors, changes resulting
from healthcare policy, dependence upon third-party vendors, timing
of regulatory approvals, the impact of pandemics or other
disasters, and other risks discussed in the Company's periodic and
other filings with the Securities and Exchange Commission. By
making these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release. There can be no assurance that the
Company will recognize revenue related to its purchase orders and
other commitments because some of these purchase orders and other
commitments are subject to contingencies that are outside of the
Company's control and may be revised, modified, delayed, or
canceled.
Company Contacts:David L.
FischelChairman and Chief Executive Officer
Kimberly PeeryChief Financial Officer
314-678-6100investors@stereotaxis.com
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Apr 2023 to Apr 2024